Since then, new generations, like liraglutide in 2010, once-weekly dulaglutide in 2014, and oral semaglutide in 2019, have arrived roughly every few years, each improving convenience, potency, and durability
Development of a gut microbe- targeted nonlethal therapeutic to inhibit thrombosis potential
The Scientific Evidence Ozempic, known generically as semaglutide, is primarily FDA-approved for the treatment of type 2 diabetes and the reduction of cardiovascular risk in adults with known heart disease
Retatrutide does not require cycling based on current clinical trial data, where participants used it continuously for 48 weeks
Additionally, SS-31 helps protect renal cells from damage, potentially reducing the severity and improving recovery in acute kidney injury through mitochondrial stabilization and oxidative stress reduction